Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITE: Remodulin Induction to Orenitram in PAH
NCT03497689Phase 4Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Jan 2019; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03497689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497689.